Recursion Pharmaceuticals (RXRX) has been drawing investor attention after recent trading shifts, with the stock closing at US$3.01 and showing mixed performance over the past week, month, and past ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid ...

Wondering whether Recursion Pharmaceuticals at around US$3.39 is a bargain or a value trap? This article focuses squarely on what the current share price might be telling you about the business. The ...

A2Z Cust2Mate Solutions Corp. (AZ) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to a loss of $0.19 per share a year ago.

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predi ...

Uber COO Andrew Macdonald gave voice to the growing concerns that, despite spending big on AI, companies aren't seeing meaningful returns.

Richard Socher's new $650 million startup wants to build an AI that can research and improve itself indefinitely — and he ...

UIUC and Stanford's RecursiveMAS lets AI agents collaborate in embedding space instead of text, cutting token usage by 75% ...

Literature’s magnetic pull relies on the belief that a kindred consciousness is speaking to the reader intimately across time ...

According to the job description, the role involves reasoning about threats that may not yet exist but could emerge rapidly ...

ADMA Biologics lowered its 2026 revenue guidance after reporting flat first-quarter sales and intensified competition in the ...

Isomorphic, which formed as an Alphabet company in 2021, has a massive cash horde, but it’s tight-lipped on what drugs it ...